| 25/01 | North American Morning Briefing: Microsoft -2- |  |
| 09/01 | North American Morning Briefing: 'Soft Landing' -3- | |
| 06/01 | Century Therapeutics' Pipeline Prioritization Plans Indicate Declining Natural Killer C.. | |
| 06/01 | Top Midday Decliners | |
| 06/01 | December Jobs Report Showing Easing Wage Pressures Lift US Equity Futures | |
| 06/01 | Top Premarket Decliners | |
| 06/01 | North American Morning Briefing: Stock Futures Soft as I.. | |
| 06/01 | Fate Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Potential Securities Cla.. | |
| 05/01 | Fate Therapeutics Inc: Termination of a Material Definitive Agreement, Costs Associated w.. | |
| 05/01 | Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, E.. | |
| 05/01 | Fate Therapeutics, Inc. Receives Notice of Termination from Janssen Biotech,Inc. of the.. | |
| 05/01 | Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeli.. | |
| 05/01 | Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeli.. | |
| 04/01 | North American Morning Briefing: Futures Rise -2- | |
| 2022 | Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemothe.. | |
| 2022 | Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemothe.. | |
| 2022 | GT Biopharma, Fate Therapeutics Say Preclinical Data Shows Potential of New Approach to.. | |
| 2022 | Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derive.. | |
| 2022 | Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multi.. | |
| 2022 | Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multi.. | |
| 2022 | Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derive.. | |
| 2022 | Fate Therapeutics Announces Clinical Safety and Activity Data of First-Ever iPSC-Derive.. | |
| 2022 | Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derive.. | |
| 2022 | Ono Exercises Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors Gen.. | |
| 2022 | Fate Therapeutics Inc: Entry into a Material Definitive Agreement, Regulation FD Disclosu.. | |
| 2022 | Fate Therapeutics, Inc. and Ono Pharmaceutical Co., Ltd. Enters into Letter Agreement i.. | |
| 2022 | Fate Therapeutics Says ONO Pharmaceutical Exercises Option to Product Candidate for Sol.. | |
| 2022 | Fate Therapeutics to Present at Upcoming Investor Conferences | |
| 2022 | Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted C.. | |
| 2022 | Fate Therapeutics to Present at Upcoming Investor Conferences | |
| 2022 | Fate Therapeutics to Present at Upcoming Investor Conferences | |
| 2022 | Fate Therapeutics: Q3 Earnings Snapshot | |
| 2022 | FATE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and .. | |
| 2022 | Fate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months .. | |
| 2022 | Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operation.. | |
| 2022 | Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at.. | |
| 2022 | Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at.. | |
| 2022 | Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Res.. | |
| 2022 | Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Res.. | |
| 2022 | Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at.. | |
| 2022 | Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at.. | |
| 2022 | Fate Therapeutics to Participate at Upcoming September Investor Conferences | |
| 2022 | Fate Therapeutics to Participate at Upcoming September Investor Conferences | |
| 2022 | Insider Sell: Fate Therapeutics | |
| 2022 | Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8?? T .. | |
| 2022 | Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8&alph.. | |
| 2022 | Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8&alph.. | |
| 2022 | Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8aß T .. | |
| 2022 | Fate Therapeutics: Q2 Earnings Snapshot | |
| 2022 | FATE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and .. | |
| 2022 | Fate Therapeutics: Reports Second Quarter 2022 Financial Results and Highlights Operation.. | |
| 2022 | Fate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months .. | |
| 2022 | Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operatio.. | |
| 2022 | Earnings Flash (FATE) FATE THERAPEUTICS Reports Q2 Revenue $18.5M | |
| 2022 | Insider Sell: Fate Therapeutics | |
| 2022 | Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Re.. | |
| 2022 | Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Re.. | |
| 2022 | North American Morning Briefing: Stock Futures -2- | |
| 2022 | Insider Sell: Fate Therapeutics | |
| 2022 | Insider Sell: Fate Therapeutics | |
| 2022 | Fate Therapeutics: Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutic.. | |
| 2022 | Fate Therapeutics Appoints Brian Powl as Chief Commercial Officer | |
| 2022 | Fate Therapeutics Inc: Entry into a Material Definitive Agreement, Regulation FD Disclosu.. | |
| 2022 | Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer | |
| 2022 | Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer | |
| 2022 | Fate Therapeutics, Inc. Appoints Brian T. Powl as Chief Commercial Officer | |
| 2022 | ONO Announces Expanded Collaboration with Fate Therapeutics on iPSC-derived CAR-T Cell .. | |
| 2022 | Fate Therapeutics Expands Collaboration with ONO Pharmaceutical for Solid Tumor Immunot.. | |
| 2022 | Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceuti.. | |
| 2022 | Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceuti.. | |
| 2022 | Fate Therapeutics, Inc. Announces Expansion of Solid Tumor Collaboration with Ono Pharm.. | |
| 2022 | Fate Therapeutics Inc: Change in Directors or Principal Officers, Submission of Matters t.. | |
| 2022 | Fate Therapeutics Shares Tumble Amid Lower-Than-Average Trading Volume | |
| 2022 | Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference | |
| 2022 | Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference | |
| 2022 | Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference | |
| 2022 | Fate Therapeutics to Present at Upcoming May Investor Conferences | |
| 2022 | Fate Therapeutics to Present at Upcoming May Investor Conferences | |
| 2022 | Fate Therapeutics to Present at Upcoming May Investor Conferences | |
| 2022 | FATE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and .. | |
| 2022 | Fate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, .. | |
| 2022 | Fate Therapeutics: Q1 Earnings Snapshot | |
| 2022 | Earnings Flash (FATE) FATE THERAPEUTICS Posts Q1 Revenue $18.4M | |
| 2022 | Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operation.. | |
| 2022 | Insider Sell: Fate Therapeutics | |
| 2022 | Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Res.. | |
| 2022 | Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Res.. | |
| 2022 | Insider Sell: Fate Therapeutics | |
| 2022 | Insider Sell: Fate Therapeutics | |
| 2022 | Fate Therapeutics to Present at Upcoming March Investor Conferences | |
| 2022 | Fate Therapeutics: Reports Fourth Quarter and Full Year 2021 Financial Results and Highli.. | |
| 2022 | Fate Therapeutics: Q4 Earnings Snapshot | |
| 2022 | FATE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and .. | |
| 2022 | Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2.. | |
| 2022 | Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December .. | |
| 2022 | Earnings Flash (FATE) FATE THERAPEUTICS Posts Q4 Revenue $17.1M | |
| 2022 | Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highl.. | |
| 2022 | Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highl.. | |
| 2022 | Fate Therapeutics, Inc. Provides Earnings Guidance for the Year Ending December 31, 202.. | |
| 2022 | Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 202.. | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Nederlands (Nederland)
Nederlands (België)
Rapporto
